Data Comparing Navidea’s AZD4694 to Gold-Standard 11C-PIB in Beta Amyloid Imaging Presented at Society of Nuclear Medicine Meeting
13:00 EDT 11 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Navidea Biopharmaceuticals, Inc. (NYSE Mkt: NAVB), a specialty
pharmaceutical company focused on precision diagnostic
radiopharmaceuticals, today announced that clinical data comparing its
amyloid imaging candidate, AZD4694, to ...
Other Sources for this Article
Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP &
CFO, 614-822-2330
More From BioPortfolio on "Data Comparing Navidea’s AZD4694 to Gold-Standard 11C-PIB in Beta Amyloid Imaging Presented at Society of Nuclear Medicine Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
